The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 359:2613-2614 December 11, 2008 Number 24
NextNext

Bortezomib plus Melphalan and Prednisone for Multiple Myeloma

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Durie, B. G.M.
-Related Article
by San Miguel, J. F.
-PubMed Citation
To the Editor: San Miguel et al. (Aug. 28 issue)1 state that the standard treatment for patients with multiple myeloma who are not candidates for high-dose therapy is melphalan and prednisone. In the light of recent studies,2,3 we do not think this statement is valid. Lenalidomide and dexamethasone are the most effective treatment in patients with multiple myeloma who are not candidates for high-dose therapy. Furthermore, unlike bortezomib, lenalidomide can be given orally and with minimal toxic side effects. There is also evidence that with lenalidomide and dexamethasone, the response rate among patients with untreated myeloma is higher (more than . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.